Polypeptide targeting HVEM protein

By designing a polypeptide that can specifically bind to HVEM protein, preventing HVEM protein from binding to BTLA, the problem of inhibiting T cell activation by HVEM protein in the prior art is solved, and the effect of enhancing T cell response and immunotherapy is achieved, with high affinity and selectively suitable for the treatment of cancer and autoimmune diseases.

CN118994312APending Publication Date: 2024-11-22BEIJING UNIV OF CHEM TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310548331.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-16
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The development of existing immune checkpoint inhibitor drugs mainly focuses on antibody drugs, with high R&D costs, long cycles and immunogenicity problems. The development of polypeptide inhibitors against the BTLA/HVEM pathway is relatively limited and cannot effectively eliminate the HVEM protein pair. Inhibition of T cell activation.

Method used

A polypeptide capable of specifically binding to HVEM protein is designed, a cyclic peptide or an amide, ester or salt formed by a disulfide bond between cysteines in its sequence, with high affinity and selectivity, preventing HVEM The protein binds to BTLA, thereby enhancing the T cell response.

Benefits of technology

This peptide can effectively block the binding of BTLA/HVEM protein, relieve the immunosuppression of HVEM protein on T cells, and show excellent ability to relieve "immune escape". It has strong targeting, excellent biocompatibility and few drug interactions. , fast drug effect and weak drug resistance, and is suitable for the diagnosis, prevention and treatment of cancer and autoimmune diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118994312A_ABST
    Figure CN118994312A_ABST
Patent Text Reader

Abstract

The invention relates to a polypeptide capable of specifically binding to HVEM protein, and a composition and application thereof. The polypeptide has high affinity and high selectivity with HVEM protein, and prevents the HVEM protein from being combined with BTLA protein after being combined with the HVEM protein, so that inhibition on T cell activation is avoided, T cell response is enhanced, and the polypeptide can be used for diagnosing and treating cancers and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and in particular relates to a polypeptide capable of specifically binding to HVEM protein, a composition thereof and an application thereof. Background Art

[0002] Cancer is a disease caused by abnormal cell proliferation and malignant transformation. These abnormal cells divide uncontrollably and form tumors, thereby destroying the functions of normal tissues and organs. Traditional treatments for cancer mainly include surgery, radiotherapy, chemotherapy, and targeted drug therapy. However, each of these four methods has its own limitations. For example, surgical resection is a traumatic treatment method with postoperative complications, inability to resolve problems such as micro-lesions and metastatic lesions; radiotherapy and chemotherapy not only kill cancer cells, but also have significant toxic side effects on healthy cells and normal tissues and organs; targeted drugs are prone to drug resistance, resulting in a gradual weakening of the therapeutic effect. At the same time, the heterogeneity of targeted proteins may also lead to large differences in the therapeutic effect.

[0003] During the immune response, checkpoint proteins on the surface of immune cells regulate the activation and function of T cells and other immune cells by interacting with their corresponding ligands, thereby controlling the intensity and scope of the body's immune response. Under normal circumstances, these immune checkpoint proteins can help maintain the body's immune balance and avoid excessive immune responses and autoimmune reactions. However, in certain cases, such as diseases such as cancer, tumor cells and other immune escape mechanisms can use these immune checkpoint proteins to inhibit the activation and effects of immune cells, thereby escaping immune surveillance and attack. Therefore, immune checkpoint proteins have become an important immunotherapy target, and their inhibitors have been widely studied and applied in the treatment of diseases such as tumors.

[0004] B and T lymphocyte attenuator (BTLA) is an immune checkpoint inhibitory receptor similar to CTLA-4 and PD-1. It regulates T cell activation by binding to its only ligand, the herpes virus entry mediator (HVEM). Cancer cells overexpress HVEM protein, which binds to BTLA on the surface of T cells, causing the recruitment of SHP-1 and SHP-2 in T cells, thereby downregulating TCR signal transduction and transmitting inhibitory signals. At the same time, the Grb-2 binding motif binds to Grb-2, leading to the recruitment of PI3K protein subunit p85 and the stimulation of the PI3K signaling pathway, thereby affecting cell function.

[0005] As of 2022, the FDA-approved immune checkpoint inhibitors only target four targets: PD-1, PD-L1, CTLA-4, and LAG3. Most immune checkpoint proteins have not been developed, and the development of combined immunosuppressants is therefore greatly restricted. At the same time, the development of immune checkpoint inhibitors is mainly focused on antibody drugs, which have the characteristics of high R&D costs, long cycles, and immunogenicity. At present, the development of peptide inhibitors for the BTLA / HVEM pathway is relatively limited, and most of them are selected and optimized based on known sequence information in nature through reasonable selection or rational mutation. Summary of the invention

[0006] The purpose of the present invention is to provide a polypeptide that can specifically bind to the HVEM protein, that is, a polypeptide targeting the HVEM protein, wherein the polypeptide has high affinity and high selectivity to the HVEM protein, and after binding to the HVEM protein, it prevents the HVEM protein from binding to BTLA, thereby avoiding the inhibition of T cell activation and enhancing T cell response, and can be used for the diagnosis and treatment of cancer, etc.

[0007] According to the first aspect of the present invention, the present invention relates to a polypeptide or a cyclic peptide formed by a disulfide bond between cysteines in its sequence, or an amide, ester or salt thereof, wherein the polypeptide has a sequence selected from the following:

[0008] P1: Gly-Cys-Thr-Cys-Pro-Arg-Gly-Trp-Val-Cys-Leu-Ala-Arg-Glu-Pro-Cys;

[0009] P2: Gly-Cys-Arg-Cys-Gln-Ser-Lys-Pro-Trp-Cys-Arg-Ala-Arg-Val-Glu-Cys.

[0010] According to the present invention, the cyclic peptide of P1 is selected from:

[0011]

[0012]

[0013] in, Indicates that the side chains of two Cys form a disulfide bond.

[0014] According to the present invention, the cyclic peptide of P2 is selected from:

[0015] P2-c(1-3,2-4):

[0016]

[0017] in, Indicates that the side chains of two Cys form a disulfide bond.

[0018] In the present invention, the three-letter abbreviations recognized in the art are used to represent the amino acid residues constituting the polypeptides of the present invention. Unless the abbreviation is preceded by "D", the amino acid represented by the abbreviation is an L-amino acid.

[0019] According to the present invention, "amide" means a derivative of the N-terminal amino group, such as but not limited to acetamide, formamide, trifluoroacetamide, benzamide, 2-aminobenzamide, chloroacetamide, bromoacetamide and the like.

[0020] According to the present invention, "ester" means a derivative of a C-terminal carboxylic acid, such as methyl ester, ethyl ester, n-propyl ester, isopropyl ester, n-butyl ester, cyclopentyl ester, cyclohexyl ester, phenyl ester, benzyl ester, pivaloyloxymethyl ester, and the like.

[0021] According to the present invention, "salt" means a pharmaceutically acceptable salt, including salts formed with acids and / or bases. Salts formed with acids include salts formed with inorganic acids or organic acids. Salts formed with inorganic acids include hydrochlorides, sulfates, hydrobromides, nitrates, phosphates, etc. Salts formed with organic acids include acetates, propionates, glycolates, oxalates, trifluoroacetates, pamoates, malonates, benzoates, toluenesulfonates, maleates, succinates, fumarates, citrates, salicylates, tartrates, etc. Salts formed with bases include ammonium salts, sodium salts, potassium salts, calcium salts, magnesium salts, silver salts, zinc salts, copper salts, etc.

[0022] The polypeptide of the present invention or the cyclic peptide formed by the disulfide bond between the cysteines in its sequence, or its amide, ester or salt can be synthesized by methods known to those skilled in the art, such as solid phase synthesis, and purified by methods known to those skilled in the art, such as high performance liquid chromatography, etc.

[0023] The polypeptide of the present invention or the cyclic peptide formed by the disulfide bond between the cysteines in its sequence, or its amide, ester or salt can specifically bind to the HVEM protein and inhibit its function, preventing it from binding to BTLA, avoiding the inhibition of T cell activation caused by the binding of the HVEM protein to BTLA, thereby enhancing the T cell response, and can be used for the diagnosis, prevention and / or treatment of HVEM-mediated related diseases such as cancer and autoimmune diseases.

[0024] According to a second aspect of the present invention, the present invention relates to the use of the polypeptide of the present invention or a cyclic peptide formed by a disulfide bond between cysteines in its sequence, or an amide, ester or salt thereof in the preparation of an HVEM inhibitor.

[0025] The present invention also relates to the use of the polypeptide of the present invention or a cyclic peptide formed by disulfide bonds between cysteines in its sequence, or an amide, ester or salt thereof in the preparation of a drug for preventing and / or treating related diseases mediated by HVEM.

[0026] The present invention also relates to the use of the polypeptide of the present invention or a cyclic peptide formed by disulfide bonds between cysteines in its sequence, or an amide, ester or salt thereof in the preparation of reagents for diagnosing diseases mediated by HVEM.

[0027] According to the third aspect of the present invention, the present invention relates to a method for preventing and / or treating related diseases mediated by HVEM, wherein an effective amount of the polypeptide of the present invention or a cyclic peptide formed by a disulfide bond between cysteines in its sequence, or an amide, ester or salt thereof is administered to an individual in need.

[0028] The present invention also relates to a method for diagnosing HVEM-mediated diseases, wherein a fluorescent probe containing the polypeptide of the present invention or a cyclic peptide formed by a disulfide bond between cysteines in its sequence, or an amide, ester or salt thereof is used.

[0029] According to the present invention, the HVEM inhibitor can be used to prevent and / or treat diseases mediated by HVEM.

[0030] According to the present invention, the related diseases mediated by HVEM include, but are not limited to, cancer, autoimmune diseases, etc. Cancers such as solid tumors or blood malignancies include, but are not limited to, lung cancer such as non-small cell lung cancer, urothelial carcinoma, head and neck leukoma, classical Hodgkin's lymphoma, bladder cancer, melanoma, thyroid cancer, breast cancer, prostate cancer, cervical cancer, ovarian cancer, colon cancer, rectal cancer, gastric cancer, liver cancer, kidney cancer, bladder cancer, nasopharyngeal cancer, laryngeal cancer, esophageal cancer, retinoblastoma, etc.; autoimmune diseases include, but are not limited to, rheumatoid arthritis, lupus erythematosus, transplant rejection, etc.

[0031] In some embodiments of the present invention, the HVEM inhibitor is used to regulate the immune response of a subject. Regulating the immune response of a subject includes enhancing the immune response of the subject, such as enhancing the proliferation of T cells of the subject or activating T cells of the subject. In one embodiment of the present invention, the HVEM inhibitor competitively binds to the HVEM protein, prevents the HVEM protein from binding to BTLA, and relieves the inhibition of BTLA on T cell activation or proliferation, thereby achieving the effect of enhancing the immune response.

[0032] In some embodiments of the present invention, the polypeptide of the present invention or the cyclic peptide formed by the disulfide bond between the cysteines in its sequence, or its amide, ester or salt is used in the preparation of an immunotherapy drug for tumors. According to the present invention, the polypeptide of the present invention or the cyclic peptide formed by the disulfide bond between the cysteines in its sequence, or its amide, ester or salt achieves the effect of treating tumors by enhancing the immune response of the user.

[0033] According to the fourth aspect of the present invention, the present invention relates to a pharmaceutical composition containing the polypeptide of the present invention or a cyclic peptide formed by a disulfide bond between cysteines in its sequence, or at least one of its amides, esters or salts, and a pharmaceutically acceptable carrier.

[0034] Those skilled in the art know how to prepare a pharmaceutical composition containing the polypeptide of the present invention or a cyclic peptide formed by a disulfide bond between cysteines in its sequence, or an amide, ester or salt thereof.

[0035] The pharmaceutical composition of the present invention can be prepared into various conventional dosage forms known in the art, including but not limited to, tablets suitable for oral administration (including various coated tablets, sustained-release or controlled-release tablets), lozenges, capsules (including soft capsules and hard capsules), granules, dispersible powders, aqueous or oily suspensions, emulsions, elixirs or syrups, etc.; creams, ointments, gels, aqueous or oily solutions or suspensions, etc. suitable for topical use; powders or liquid aerosols suitable for inhalation, sterile aqueous or oily intravenous, subcutaneous or intramuscular injections, suppositories, etc. suitable for parenteral administration.

[0036] The pharmaceutically acceptable carriers of the present invention include, but are not limited to, various conventional organic or inorganic drug carriers, such as excipients, lubricants, binders, disintegrants, water-soluble polymers, inorganic salts, solvents, dissolution aids, suspending agents, isotonic agents, buffers, preservatives, antioxidants, colorants, sweeteners, acidulants, foaming agents and flavoring agents, etc.

[0037] Those skilled in the art know that in the pharmaceutical composition of the present invention, the appropriate amount of the polypeptide of the present invention or the cyclic peptide formed by the disulfide bond between the cysteines in its sequence, or its amide, ester or salt, and a pharmaceutically acceptable carrier as an active ingredient can be determined according to conventional methods in the art.

[0038] The present invention also relates to a detection or diagnostic reagent or kit, which contains the polypeptide of the present invention or a cyclic peptide formed by a disulfide bond between cysteines in its sequence, or at least one of its amides, esters or salts.

[0039] Compared with the prior art, the present invention has the following beneficial effects:

[0040] (1) The polypeptide of the present invention has the advantages of both antibody drugs and small molecule drugs, with strong targeting, excellent biocompatibility, few drug interactions, fast drug efficacy, weak drug resistance, and relatively low R&D and production costs.

[0041] (2) The polypeptide of the present invention has high affinity, high purity, and low toxicity. It can specifically bind to HVEM protein overexpressed on the surface of tumor cells and the like, has high sensitivity, and can be used in the screening, diagnosis, prevention, and treatment of tumors and the like.

[0042] (3) The polypeptide of the present invention has a good HVEM targeting effect and can be used as a target molecule of a targeted drug delivery system or a gene drug carrier. It is safe and reliable and has a very broad application prospect in the field of tumor treatment.

[0043] (4) The polypeptide of the present invention can effectively block the binding of BTLA / HVEM proteins, relieve the immunosuppression of T cells by HVEM proteins, and show an excellent ability to relieve "immune escape", and can be used as a lead drug targeting immune checkpoints. BRIEF DESCRIPTION OF THE DRAWINGS

[0044] Figure 1 is the mass spectrum of P1;

[0045] Figure 2 is the HPLC profile of P1;

[0046] Figure 3 is the mass spectrum of P2;

[0047] Figure 4 is the HPLC chart of P2;

[0048] Figure 5 is the mass spectrum of P1-c(1-4,2-3);

[0049] Figure 6 is the HPLC chart of P1-c(1-4,2-3);

[0050] Figure 7 is the mass spectrum of P1-c(1-3,2-4);

[0051] Figure 8 HPLC chart of P1-c (1-3, 2-4);

[0052] Fig. 9 Schematic diagram of competitive ELISA method for detecting the competitive binding of peptide and BTLA to HVEM;

[0053] Fig.10 The results of the competitive ELISA test of the competitive binding of peptides and BTLA to HVEM;

[0054] Fig.11 is the surface plasmon resonance (SPR) curve between P1 and HVEM (K D =4.09×10 -6 M);

[0055] Fig.12 is the surface plasmon resonance (SPR) curve between P2 and HVEM (K D =2.31×10 -5 M);

[0056] Fig.13 is the hemolysis test result of P1;

[0057] Fig.14 The cytotoxicity test results of P1, P1-c(1-4,2-3), and P1-c(1-3,2-4);

[0058] Fig.15 The flow cytometric results of the experiment on the release of T cell proliferation inhibition by P1, P1-c (1-4, 2-3), and P1-c (1-3, 2-4);

[0059] Fig.16 These are the experimental results of relieving the inhibition of T cell proliferation by P1, P1-c (1-4, 2-3), and P1-c (1-3, 2-4). DETAILED DESCRIPTION

[0060] The present invention will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention. In addition, it should be understood that after reading the content recorded in the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms fall within the scope limited by the present invention equally.

[0061] Example 1. Preparation of P1, P2, P1-c (1-4, 2-3), and P1-c (1-3, 2-4)

[0062] The present invention adopts solid phase synthesis method to synthesize polypeptide:

[0063] 1) Using DMF as solvent, the concentration of various protected amino acid solutions is 0.5M, the concentration of HBTU solution is 0.4M, the concentration of piperidine solution is 200ml / L, and the concentration of DIPEA solution is 0.8M. Using n-butanol as solvent, the concentration of ninhydrin solution is 150g / L. The cutting solution is TFA 89% + water 3% + EDT 2.5% + TIS 3% + Thioanisole 2.5%.

[0064] 2) Swelling of the resin: 250 μmol of dichlororesin was placed in a 10 mL peptide reactor, 5 mL of DCM was added, and the mixture was placed on a peptide rotator to swell for 1 h, and then washed with 2 mL of DMF for 3 times.

[0065] 3) Connect the first amino acid: add 1 mmol of Fmoc-Cys(Trt)-OH solution and 2 mmol of DIPEA solution to the reactor, shake for 2 h, wash with 2 ml of DMF and 2 ml of DCM three times, add 2.5 mL of methanol and shake for 1 h, wash with 2 ml of DCM and 2 ml of DMF three times.

[0066] 4) Removal of Fmoc protecting group at nitrogen end: add 5 mL of piperidine solution to the reactor, shake for 5 min, remove the solvent, add 5 mL of piperidine solution again, shake for 5 min, and remove the solvent.

[0067] 5) Detection: Take a dozen resin pellets, add 40 μL of ninhydrin solution, and heat at 105°C-110°C for 5 min. A dark blue color indicates successful deprotection.

[0068] 6) Washing: Wash 6 times with 2 mL DMF.

[0069] 7) Connecting the second amino acid: Add 1 mmol of Fmoc-Pro-OH solution, 1 mmol of HBTU solution and 2 mmol of DIPEA solution into the reactor and shake the reaction for 40 minutes.

[0070] 8) Detection: Take a dozen resin pellets, add 40 μL of ninhydrin solution, and heat at 105°C-110°C for 5 min. A colorless state indicates successful coupling.

[0071] 9) Washing: Wash 3 times with 2 mL DMF.

[0072] 10) Repeat steps 4) to 9), and connect Fmoc-Glu(OtBu)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Ala-OH, Fmoc-Leu-OH, Fmoc-Cys(Trt)-OH, Fmoc-Val-OH, Fmoc-Trp in sequence (Boc)-OH, Fmoc-Gly-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Pro-OH, Fmoc-Cys(Trt)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Gly-OH.

[0073] 11) Repeat step 4) to remove the Fmoc protecting group at the nitrogen end, and then wash with 2 mL DMF for 6 times.

[0074] 12) Cleavage of polypeptide and removal of side chain protecting groups: 5 mL of cleavage solution was added to the reactor and the oscillation cleavage time was 120 min.

[0075] 13) Preliminary purification of polypeptide: After the cutting solution was blown off with nitrogen, the polypeptide was washed 4 times with iced isopropyl ether, centrifuged at 4000 rpm for 5 min to remove the isopropyl ether, and vacuum dried to remove the residual isopropyl ether to obtain a crude polypeptide.

[0076] 14) Purification of crude polypeptide: The crude polypeptide was purified by reverse HPLC, using a C18 column, the aqueous phase was an aqueous solution containing 0.05% TFA, the organic phase was an 80% acetonitrile / water solution, and gradient elution was performed at a gradient of 1.5% per minute, and the eluate at the highest peak was collected. HPLC diagram is shown in Figure 2 .

[0077] 15) Freeze-drying: The collected eluate is placed in a freeze dryer for concentration and freeze-drying into a white powder to obtain polypeptide P1.

[0078] 16) Mass spectrometry identification: ESI-TOF-MS detection, P1 (C 72 H 115 N 23 O 20 The molecular weight of S4 is 1751, [M+2H] 2+ =876.5, [M+3H] 3+ =584.6. Mass spectrum Figure 1 .

[0079] According to the above steps, polypeptide P2 was prepared using Fmoc-Cys(Trt)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Val-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Trp(Boc)-OH, Fmoc-Pro-OH, Fmoc-Lys(Boc)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Cys(Trt)-OH, and Fmoc-Gly-OH in sequence. The mass spectrum and HPLC diagram of polypeptide P2 are shown in FIG. Figure 3 and 4 .

[0080] According to the above steps, Fmoc-Cys(Trt)-OH, Fmoc-Pro-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Ala-OH, Fmoc-Leu-OH, Fmoc-Cys(Acm)-OH, Fmoc-Val-OH, Fmoc-Trp(Boc)-OH, Fmoc-Gly-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Pro-OH, Fmoc-Cys(Acm)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Cys(Trt)-OH, and Fmoc-Gly-OH were used in sequence to prepare the second Cys4 and the third Cys10 side chain Acm-protected linear polypeptides. Then, pure water was used as solvent, 0.5 mM GSSG was used as oxidant, the peptide concentration was 5 μM, and the reaction was oscillated at room temperature for 4 hours. Steps 14), 15), and 16) were repeated to prepare a single-ring peptide with the second Cys4 and the third Cys10 side chains protected by Acm and the first Cys2 and the fourth Cys16 side chains connected by disulfide bonds. Then, pure water was used as solvent to prepare a single-ring peptide solution with a concentration of 5 μM. Under stirring, 5 mM I2 methanol solution was added dropwise to make its concentration 400 μM. The reaction was oscillated for 2 hours. Steps 14), 15), and 16) were repeated to prepare P1-c (1-4, 2-3), whose mass spectrum and HPLC diagram are shown in FIG. Figure 5 and 6 .

[0081] According to the above steps, Fmoc-Cys(Trt)-OH, Fmoc-Pro-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Ala-OH, Fmoc-Leu-OH, Fmoc-Cys(Acm)-OH, Fmoc-Val-OH, Fmoc-Trp(Boc)-OH, Fmoc-Gly-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Pro-OH, Fmoc-Cys(Trt)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Cys(Acm)-OH, and Fmoc-Gly-OH were used in sequence to prepare the first Cys2 and the third Cys10 side chain Acm protected linear polypeptides. Then, pure water was used as solvent, 0.5 mM GSSG was used as oxidant, the peptide concentration was 5 μM, and the reaction was oscillated at room temperature for 4 hours. Steps 14), 15), and 16) were repeated to prepare a single-ring peptide with the first Cys2 and the third Cys10 side chains protected by Acm and the second Cys4 and the fourth Cys16 side chains connected by disulfide bonds. Then, pure water was used as solvent to prepare a single-ring peptide solution with a concentration of 5 μM. Under stirring, 5 mM I2 methanol solution was added dropwise to make its concentration 400 μM. The reaction was oscillated for 2 hours. Steps 14), 15), and 16) were repeated to prepare P1-c (1-3, 2-4), whose mass spectra and HPLC diagrams are shown in FIG. Figure 7 and 8 .

[0082] Example 2. Competitive ELISA to detect the competitive inhibition of P1 and P2 on the binding of BTLA and HVEM

[0083] A schematic diagram of the competitive ELISA method is shown in Fig. 9 The specific steps are as follows:

[0084] 1) Dry coating of BTLA: 1×PBS was used to prepare BTLA coating solution, the concentration of BTLA was 100 ng / μL, and the coating solution was added to a high-adsorption 96-well plate, 100 μL was added to each well, and it was left open at 37°C overnight. The next day, 100 μL of anhydrous methanol was added to each well, and after fixing at room temperature for 15 minutes, the methanol was poured off, and the plate was left to dry or dried with a hair dryer.

[0085] 2) BSA blocking: Prepare 5% BSA / PBST solution and add 200 μL to each well. Incubate at room temperature for 2 h and then discard the blocking solution.

[0086] 3) Incubation of HVEM-biotin: Using PBS as solvent, prepare the test peptide solution, starting from 10μg / mL, and dilute it 5 times to obtain test peptide solutions with concentrations of 10μg / mL, 2μg / mL, 0.4μg / mL, 0.08μg / mL, 0.016μg / mL, 0.0032μg / mL, and 0.00064μg / mL, respectively. HVEM-biotin was dissolved in PBS solution to prepare a 10ng / μL protein solution. 50μL of 100ng / μL HVEM solution was added to every 100μL of polypeptide solution, and the total volume was made up to 200μL with PBS solution. Incubate 12h in advance, replace the polypeptide with an equal amount of PBS in the positive control group, and replace HVEM-biotin and polypeptide with an equal amount of PBS in the negative control. 200 μL of the peptide / HVEM-biotin protein mixed solution was added to each well of a 96-well plate, and three replicate wells were set up. After incubation at room temperature for 2 hours, the wells were washed 6 times with PBST.

[0087] 4) Incubation of HRP-streptavidin: Prepare a 1:5000 dilution of HRP-Streptavidin solution with PBST. Add 200 μL of HRP-Streptavidin solution to each well of a 96-well plate, incubate at room temperature for 2 hours, and then wash 6 times with PBST.

[0088] 5) TMB color development: Add 200 μL of TMB solution restored to room temperature to each well of the 96-well plate, incubate at room temperature for 10 min-2 h until a clear blue color is seen. Read the absorbance at 620 nm on an ELISA reader.

[0089] 6) Data processing: Inhibition Rate% = (OD test peptide - OD negative) / (OD positive - OD negative) × 100%, with the test peptide concentration as the abscissa and Inhibition Rate% as the ordinate, draw a curve, the results are shown in Fig.10 .according to Fig.10 Both P1 and P2 can competitively inhibit the binding between BTLA and HVEM proteins, and the ability of competitively inhibiting the binding between BTLA and HVEM proteins is: P1>P2.

[0090] Example 3. SPR determination of the dissociation constant KD between P1, P2 and HVEM

[0091] The CM-5 chip was fixed into the Biacore T200 chip slot, 1×PBS-P was used as the buffer, the first channel was selected as the reference channel, the ligand was not fixed, and it was used for subsequent background subtraction. HVEM and peptides were diluted in 1×PBS-P as the buffer.

[0092] 1) Fixation of HVEM: Use the second channel as the experimental channel and set the program so that only the second channel flows through the NHS+EDC mixture (200 μL, 1:1 mixture), HVEM protein solution (200 μL, 20 ng / μL, pH=5.0), and ethanolamine (140 μL) in sequence, and HVEM can be coupled and fixed on the chip.

[0093] 2) Multi-cycle affinity determination: Flow path selected 2-1, Flow rate set to 30μL / min, Contact time set to 100s, Dissociation time set to 300s, regeneration time set to 30s. Prepare a series of concentration gradient solutions by 2-fold dilution of the peptide, and place them in the sample tank for standby use. The regeneration reagent is 1M HCl solution. Set up the program to perform multi-cycle affinity determination in sequence. After deducting the nonspecific binding on the reference channel, the affinity relationship between HVEM and the peptide is obtained by analysis and fitting.

[0094] The RU-time results of SPR determination of the affinity between P1, P2 and HVEM are shown in Fig.11 , 12 .according to Fig.11 , 12 It can be seen that the affinity dissociation constant between P1 and HVEM is 4.09×10 -6 The affinity dissociation constant between M;P2 and HVEM is 2.31×10 -5 M.

[0095] Example 4. Hemolysis experiment

[0096] The hemolytic activity and biosafety of the peptides were tested by hemolytic assay.

[0097] Take fresh anticoagulated blood and centrifuge it at 4°C and 3000rpm for 10min, remove the supernatant, add 10 times the volume of 0.9% saline to the red blood cells at the bottom, mix well, centrifuge at 3000rpm for 10min, and repeat the washing until the supernatant is no longer red; transfer the red blood cells in the lower layer to saline to prepare a 2% (V / V) red blood cell saline suspension for use.

[0098] P1 was diluted with physiological saline in a 2-fold gradient to the following concentrations: 200 μM, 100 μM, 50 μM, 25 μM, 12.5 μM, 6.25 μM, 3.125 μM and 1.5625 μM as the detection concentrations.

[0099] Add 0.8 mL of P1 solution to 0.2 mL of red blood cell suspension, add an equal amount of ddH2O to the positive control, and an equal amount of physiological saline to the negative control. Incubate at 37°C for 1 hour. Centrifuge all solutions at 1600 rpm for 5 minutes, dilute the supernatant 1:1 with physiological saline, and measure the absorbance of the supernatant at 570 nm using an ELISA reader.

[0100] HR%=(OD test P1 peptide-OD negative) / (OD positive-OD negative)×100%.

[0101] A bar graph was drawn with P1 concentration as the horizontal axis and HR% as the vertical axis. The results are shown in Fig.13 . Fig.13 The results showed that the hemolysis rate of P1 at each concentration was less than 5%, indicating that P1 did not cause hemolysis.

[0102] Example 5. CCK-8 cytotoxicity assay

[0103] PBMC cells were plated with 200,000 cells (90 μL) per well 24 hours in advance. The culture medium was RPMI1640 complete culture medium supplemented with 1% double antibody and 10% FBS. The peptides were diluted and dissolved in the above culture medium, and then 10 μL of P1 and its cyclic peptide P1-c (1-4, 2-3) and P1-c (1-3, 2-4) solutions were added respectively. Three final concentrations of each peptide were set, namely 1 μM, 10 μM and 100 μM, and the total volume of each well was 100 μL. The wells with no peptide and only 10 μL of culture medium were used as positive control groups, and the wells with no cells and only 100 μL of culture medium were set as blank controls. Three replicate wells were set for each peptide and each concentration. After incubation at 37°C in a carbon dioxide incubator for 24 hours, 11 μL of CCK-8 solution was added to each well, and cultured at 37°C in a carbon dioxide incubator for 1-4 hours until obvious color development. The absorbance OD value was measured at 450 nm.

[0104] Cell viability% = (OD positive - OD polypeptide) / (OD positive - OD blank) × 100%

[0105] A bar graph was drawn with peptide concentration as the horizontal axis and Cell viability% as the vertical axis. The results are shown in Fig.14 . Fig.14 It showed that P1 and its cyclic peptides P1-c(1-4,2-3) and P1-c(1-3,2-4) had no cytotoxicity at concentrations of 1μM to 100μM.

[0106] Example 6. Experiment on the release of immune cell proliferation inhibition

[0107] 1) CFSE live cell staining: CFDA SE stock solution was prepared with DMSO at a concentration of 10 mM and diluted 1000 times with incomplete culture medium to 10 μM for later use. PBMC cells were diluted to 1×10 7 10 / mL, add an equal volume of CFSE diluent (10μM), mix by blowing gently, and incubate at 5% CO2, 37℃ for 10-15min, mixing once every 5min. Add an equal volume of complete medium and incubate for 5min to terminate the reaction, centrifuge and remove the supernatant. Repeat once. Add an appropriate amount of PBS and mix by blowing gently to adjust the PBMC cell concentration to 1×10 7 pcs / mL, for future use.

[0108] 2) T cell activation and suppression release: The PBMCs stained previously were adjusted to a concentration of 1×10 6 / mL, according to 1×10 5 Each well was added to a 96-well plate, and ConA, HVEM and polypeptide were added in sequence according to the experimental settings below, and the total volume was supplemented with complete culture medium to 200 μL.

[0109] 3) The experiment was set up as follows: ①Blank control: PBMC cells stained with CFSE, no stimulation. ②Positive control: PBMC cells stained with CFSE, stimulated with 35μg / mL ConA. ③Negative control: PBMC cells stained with CFSE, stimulated with 35μg / mL ConA, and 5μg / mL HVEM was added to inhibit PBMC proliferation. ④Experimental group: PBMC cells stained with CFSE, stimulated with 35μg / mL ConA, 5μg / mL HVEM, and added with P1, P1-c (1-3, 2-4) or P1-c (1-4, 2-3), all at a concentration of 50μg / mL.

[0110] 4) After 48 h of culture, trypsin was added to digest the cells, and the cells were collected by centrifugation. The cell pellet was resuspended in 1 mL of PBS, washed twice by centrifugation, and then resuspended in 500 μL of PBS. The results were detected by flow cytometry. Fig.15 .

[0111] Flowjo software was used to circle the CFSE-positive cells, and the Blank control was used as the basis for division. The percentage of cells in the proliferation interval to the total number of cells was calculated, which was the proliferation rate. Fig.15 .

[0112] A bar graph was drawn showing the effects of P1 and its two cyclic peptides P1-c (1-3, 2-4) and P1-c (1-4, 2-3) on the inhibition of immune cell proliferation. Fig.16 .according to Fig.16Compared with the Positive control group, the proliferation of T cells in the Negative control group was inhibited in the presence of HVEM protein, while the proliferation rate of T cells in the experimental groups to which the same concentration of P1, P1-c (1-3, 2-4) or P1-c (1-4, 2-3) was added was significantly increased, indicating that P1, P1-c (1-3, 2-4) and P1-c (1-4, 2-3) all showed the ability to relieve the inhibition of T cell proliferation.

Claims

1. A polypeptide or a cyclic peptide formed by a disulfide bond between cysteines in its sequence, or an amide, ester or salt thereof, wherein the polypeptide has a sequence selected from the group consisting of: P1: Gly-Cys-Thr-Cys-Pro-Arg-Gly-Trp-Val-Cys-Leu-Ala-Arg-Glu-Pro-Cys; P2: Gly-Cys-Arg-Cys-Gln-Ser-Lys-Pro-Trp-Cys-Arg-Ala-Arg-Val-Glu-Cys.

2. The polypeptide of claim 1 or a cyclic peptide formed by a disulfide bond between cysteines in its sequence, or an amide, ester or salt thereof, wherein the cyclic peptide of P1 is selected from: P1-c(1-3,2-4): P1-c(1-4,2-3):

3. The polypeptide of claim 1 or a cyclic peptide formed by a disulfide bond between cysteines in its sequence, or an amide, ester or salt thereof, wherein the cyclic peptide of P2 is selected from: P2-c(1-3,2-4): P2-c(1-4,2-3):

4. Use of the polypeptide according to any one of claims 1 to 3 or a cyclic peptide formed by disulfide bonds between cysteines in its sequence, or an amide, ester or salt thereof in the preparation of an HVEM inhibitor; Preferably, the HVEM inhibitor modulates an immune response in a subject; preferably, the HVEM inhibitor enhances proliferation of T cells in a subject or activates T cells in a subject.

5. Use of the polypeptide according to any one of claims 1 to 3 or a cyclic peptide formed by disulfide bonds between cysteines in its sequence, or an amide, ester or salt thereof in the preparation of a medicament for preventing and / or treating HVEM-mediated diseases.

6. Use of the polypeptide according to any one of claims 1 to 3 or a cyclic peptide formed by disulfide bonds between cysteines in its sequence, or an amide, ester or salt thereof in the preparation of an agent for diagnosing HVEM-mediated diseases.

7. The use according to claim 5 or 6, in, The related diseases mediated by HVEM are selected from cancer and autoimmune diseases.

8. A pharmaceutical composition comprising the polypeptide according to any one of claims 1 to 3 or a cyclic peptide formed by disulfide bonds between cysteines in its sequence, or at least one of its amides, esters or salts, and a pharmaceutically acceptable carrier.

9. A detection or diagnostic reagent or kit, comprising the polypeptide according to any one of claims 1 to 3 or a cyclic peptide formed by disulfide bonds between cysteines in its sequence, or at least one of its amides, esters or salts.

10. Use of the polypeptide according to any one of claims 1 to 3 or a cyclic peptide formed by disulfide bonds between cysteines in its sequence, or an amide, ester or salt thereof in the preparation of a drug for immunotherapy of tumors.